Economic Evaluation of Qdenga Compared with Standard of Care in the Singapore General Population from the Healthcare Payer Perspective

The research objective is to use the TRUST platform to produce estimates relevant for the calculation of the burden of disease and cost-effectiveness analysis purposes. The study will quantify Singapore’s dengue burden (incidence, severity, resource use, and direct medical costs) by age and other strata, analyse temporal trends and financial impact, and evaluate Qdenga’s cost-effectiveness versus current standard care over a lifetime horizon from the healthcare system perspective.

The analysis comprises a burden-of-disease assessment and a cost-utility analysis estimating incremental disability-adjusted life years (obtained from the publicly available literature) and ICERs. Cost-effectiveness will be examined via two complementary models: a transmission-informed framework leveraging outputs from an external dynamic model (Model A) [8-10] and a de novo state-transition health-state model (Model B). Robustness will be assessed through extensive deterministic, probabilistic, and scenario analyses, addressing parameter and structural uncertainty.